BZLF1 controlled by family repeat domain induces lytic cytotoxicity in Epstein-Barr virus-positive tumor cells

被引:0
作者
Wang, H
Zhao, Y
Zeng, L
Tang, M
El-Deeb, A
Li, JJ
Cao, Y
机构
[1] City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Oncol, Duarte, CA 91010 USA
[2] Cent S Univ, Xiangya Sch Med, Canc Res Inst, Changsha 410078, Hunan, Peoples R China
关键词
gene therapy; Epstein-Barr virus; BZLF1; lytic replication;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: BZLF1, an EBV (Epstein-Barr virus) immediate early gene, is required for EBV lytic replication that causes the death of host cells. EBNA1, the product of EBV latent gene, binds to the family repeats (FR) of the origin of replication (Orip) regulating EBV replication. Materials and Methods: A vector pFR-Z (BZLF1 controlled by FR domain of EBV) was constructed and transfected into EBV-positive 5-8F and-negative HNE3 nasopharyngeal carcinoma cells and BZLF1-induced cytotoxicity was tested. Results: EBNA1 expression was detected in 5-8F but not HNE3 cells and, in agreement, pFR controlled luciferase expression was activated in 5-8F cells but inhibited in HNE3 cells. Gardella gel assay demonstrated that pFR-Z effectively induced EBV lytic replication in 5-8F but not HNE3 cells. The lytic cytotoxicity was confirmed by a diminished cell survival and the induction of lytic proteins EA-D and gp125. The cytotoxicity was also strikingly enhanced by addition of GCV (gancyclovir) that kill cells with lytic form EBV Conclusion: pFR-Z is a specific gene therapy vehicle for EBV-positive carcinomas.
引用
收藏
页码:67 / 74
页数:8
相关论文
共 37 条
  • [11] DETECTION OF CIRCULAR AND LINEAR HERPESVIRUS DNA-MOLECULES IN MAMMALIAN-CELLS BY GEL-ELECTROPHORESIS
    GARDELLA, T
    MEDVECZKY, P
    SAIRENJI, T
    MULDER, C
    [J]. JOURNAL OF VIROLOGY, 1984, 50 (01) : 248 - 254
  • [12] Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses
    Guo, GZ
    Yan-Sanders, Y
    Lyn-Cook, BD
    Wang, TL
    Tamae, D
    Ogi, J
    Khaletskiy, A
    Li, ZK
    Weydert, C
    Longmate, JA
    Huang, TT
    Spitz, DR
    Oberley, LW
    Li, JJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (07) : 2362 - 2378
  • [13] HAMILTONDUTOIT SJ, 1993, AM J PATHOL, V143, P1072
  • [14] EPSTEIN-BARR VIRUS IN NASAL T-CELL LYMPHOMAS IN PATIENTS WITH LETHAL MIDLINE GRANULOMA
    HARABUCHI, Y
    YAMANAKA, N
    KATAURA, A
    IMAI, S
    KINOSHITA, T
    MIZUNO, F
    OSATO, T
    [J]. LANCET, 1990, 335 (8682) : 128 - 130
  • [15] SEQUENCE REQUIREMENTS OF THE EPSTEIN-BARR-VIRUS LATENT ORIGIN OF DNA-REPLICATION
    HARRISON, S
    FISENNE, K
    HEARING, J
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (03) : 1913 - 1925
  • [16] Histone acetylation and reactivation of Epstein-Barr virus from latency
    Jenkins, PJ
    Binné, UK
    Farrell, PJ
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (02) : 710 - 720
  • [17] Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia
    Judde, JG
    Spangler, G
    Magrath, I
    Bhatia, K
    [J]. HUMAN GENE THERAPY, 1996, 7 (05) : 647 - 653
  • [18] Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: Comparison of two different Epstein-Barr virus-based vectors
    Kenney, S
    Ge, JQ
    Westphal, EM
    Olsen, J
    [J]. HUMAN GENE THERAPY, 1998, 9 (08) : 1131 - 1141
  • [19] EPSTEIN-BARR-VIRUS - INCREASING EVIDENCE OF A LINK TO CARCINOMA
    KIEFF, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (11) : 724 - 726
  • [20] KIEFF E, 1996, VIROLOGY, P2397